A5076270097- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Thyroid Cancer Diagnosis and Treatment
- Pancreatitis Pathology and Treatment
- Thyroid and Parathyroid Surgery
- Epigenetics and DNA Methylation
- Parathyroid Disorders and Treatments
- Pituitary Gland Disorders and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Adrenal and Paraganglionic Tumors
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Neuroblastoma Research and Treatments
- Gallbladder and Bile Duct Disorders
- Hepatocellular Carcinoma Treatment and Prognosis
- Esophageal Cancer Research and Treatment
- Cancer Cells and Metastasis
- Colorectal Cancer Screening and Detection
- Hormonal Regulation and Hypertension
- Head and Neck Anomalies
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways
Medical College of Wisconsin
2016-2025
Twitter (United States)
2024
University Hospitals of North Midlands NHS Trust
2023-2024
National Institute for Occupational Safety and Health
2023
Royal Stoke University Hospital
2023
Pancreatic Cancer Action Network
2023
Versiti Blood Center of Wisconsin
2021
Icahn School of Medicine at Mount Sinai
2021
Froedtert Hospital
2011-2019
University of Wisconsin–Milwaukee
2015
Abstract Pancreatic adenocarcinoma is characterized by a dense background of tumor associated stroma originating from abundant pancreatic stellate cells. The aim this study was to determine the effect human cells (HPSC) on progression. HPSCs were isolated resected samples and immortalized with telomerase SV40 large T antigen. Effects HPSC conditioned medium (HPSC-CM) in vitro proliferation, migration, invasion, soft-agar colony formation, survival presence gemcitabine or radiation therapy...
Chemoradiation prior to pancreaticoduodenectomy ensures that all patients who undergo resection complete multimodality therapy, avoids in with rapidly progressive disease, and allows radiation therapy be delivered well-oxygenated cells before surgical devascularization. Twenty-eight cytologic or histologic proof of localized adenocarcinoma the pancreatic head received preoperative chemoradiation (fluorouracil, 300 mg/m2 per day, 50.4 Gy) intent proceeding resection; 28 completed this...
We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma.Eligible with head/uncinate process adenocarcinoma radiographically defined potentially resectable disease 7 weekly intravenous (IV) infusions gemcitabine (400 mg/m(2) IV over 30 minutes) plus radiation therapy (30 Gy in 10 fractions 2 weeks). Patients underwent restaging 4 6 weeks after...
Purpose The role of systemic chemotherapy in the management pancreatic endocrine carcinoma (islet cell carcinoma; PEC) is an area considerable controversy. Response rates ranging from 6% to 69% have been reported for streptozocin-based chemotherapy. We retrospectively studied 84 patients with locally advanced or metastatic PEC who had treated fluorouracil, doxorubicin, and streptozocin (FAS) determine objective response rate, duration progression-free survival (PFS), overall (OS). Patients...
In Brief Objective: To better understand the impact of a microscopically positive margin (R1) on patterns disease recurrence and survival after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma. Summary Background Data: A resection PD is considered to be poor prognostic factor, some have proposed that an R1 may biologic predictor more aggressive disease. The natural history patients treated with contemporary multimodality therapy who underwent has not been described. Methods: We...
Actual 5-year survival rates of 10–18% have been reported for patients with resected pancreatic adenocarcinoma (PC), but the use multimodality therapy was uncommon in these series. We evaluated long-term and patterns recurrence treated PC contemporary staging therapy. analyzed 329 consecutive between 1990 2002 who underwent resection. Each received a multidisciplinary evaluation standard operative approach. Pre- or postoperative chemotherapy and/or chemoradiation were routine. Surgical...
We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma.Chemotherapy consisted (750 mg/m(2)) (30 given every 2 weeks four doses. Chemoradiation weekly infusions (400 combined radiation therapy Gy 10 fractions administered over weeks) delivered 5 days per week. Patients underwent restaging 4 6 after completion and, the absence disease...
Nuclear factor kappaB (NF-kappaB) and activator protein 1 (AP-1) transcription factors regulate many important biological pathological processes. Activation of NF-kappaB is regulated by the inducible phosphorylation inhibitor IkappaB kinase. In contrast, Fos, a key component AP-1, primarily transcriptionally serum responsive (SRFs) ternary complex (TCFs). Despite these different regulatory mechanisms, there an intriguing possibility that AP-1 may modulate each other, thus expanding scope two...
We examine the epidemiology, natural history, and prognostic factors that affect duration of survival for islet cell carcinoma by using population-based registries. The Surveillance, Epidemiology, End Results (SEER) Program database (1973–2003 release, April 2006) was used to identify cases histology codes tumor site. A total 1310 (619 women 691 men) with a median age 59 years were identified. annual age-adjusted incidence in periods covered SEER 9 (1973–1991), 13 (1992–1999), 17 (2000–2003)...